Progress in the chemotherapeutic treatment of osteosarcoma (Review)

Zhang,Ya; Yang,Jingqing; Zhao,Na; Wang,Cao; Kamar,Santosh; Zhou,Yonghong; He,Zewei; Yang,Jifei; Sun,Bin; Shi,Xiaoqian; Han,Lei; Yang,Zuozhang

doi:10.3892/ol.2018.9434

Progress in the chemotherapeutic treatment of osteosarcoma (Review)

Authors:
- Ya Zhang
- Jingqing Yang
- Na Zhao
- Cao Wang
- Santosh Kamar
- Yonghong Zhou
- Zewei He
- Jifei Yang
- Bin Sun
- Xiaoqian Shi
- Lei Han
- Zuozhang Yang
View Affiliations

Affiliations: Department of Orthopedics, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118, P.R. China, Department of Orthopedics, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China, Department of Pharmacy, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118, P.R. China, Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China
Published online on: September 12, 2018 https://doi.org/10.3892/ol.2018.9434
Pages: 6228-6237

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is the most common type of primary bone tumor in children and adolescents and has been associated with a high degree of malignancy, early metastasis, rapid progression and poor prognosis. However, the use of adjuvant chemotherapy improves the prognosis of patients with OS. OS chemotherapy is based primarily on the use of adriamycin, cisplatin (DDP), methotrexate (MTX), ifosfamide (IFO), epirubicin (EPI) and other drugs. Previous studies have revealed that the survival rate for patients with OS appears to have plateaued: 5‑year survival rates remain close to 60%, even with the use of combined chemotherapy. The most limiting factors include complications and fatal toxicity associated with chemotherapy agents, particularly high‑dose MTX (HD‑MTX), for which high toxicity and great individual variation in responses have been observed. Docetaxel (TXT) is a representative member of the relatively recently developed taxane class of drugs, which function to inhibit OS cell proliferation and induce apoptosis. Recently, more clinical studies have reported that TXT combined with gemcitabine (GEM) is effective in the treatment of OS (relapse/refractory and progressive), providing evidence in support of potential novel treatment strategies for this patient population. However, there is still no global consensus on this type of chemotherapy approach. The present review summarizes current studies surrounding progress in the chemotherapeutic treatment of OS and discusses the advantages and potential feasibility of TXT+GEM in the treatment of OS.

View Figures

View References

1	Genetic and Rare Diseases Information Center (GARD), supported by ORDR-NCATS and NHGRI. http://www.diseaseinfosearch.org/result/5489
2	Harrison DJ, Geller DS, Gill JD, Lewis VO and Gorlick R: Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 18:39–50. 2018. View Article : Google Scholar : PubMed/NCBI
3	Huang KL, Chen CF, Wu PK, Chen PC, Chen WM, Liu CL and Chen TH: Clinical outcomes and prognostic factors of Ewing sarcoma: A clinical analysis of 12 patients in Taiwan. J Chin Med Assoc. 75:16–20. 2012. View Article : Google Scholar : PubMed/NCBI
4	Ren L, Mendoza A, Zhu J, Briggs JW, Halsey C, Hong ES, Burkett SS, Morrow J, Lizardo MM, Osborne T, et al: Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. Oncotarget. 6:29469–29481. 2015. View Article : Google Scholar : PubMed/NCBI
5	Janeway KA and Grier HE: Sequelae of osteosarcoma medical therapy: A review of rare acute toxicities and late effects. Lancet Oncol. 11:670–678. 2010. View Article : Google Scholar : PubMed/NCBI
6	Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 118:5888–5893. 2012. View Article : Google Scholar : PubMed/NCBI
7	Friedman MA and Carter SK: The therapy of osteogenic sarcoma: Current status and thoughts for the future. J Surg Oncol. 4:482–510. 1972. View Article : Google Scholar : PubMed/NCBI
8	Marina N, Gebhardt M, Teot and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
9	Bacci G, Mercuri M, Briccoli A, Ferrari S, Bertoni F, Donati D, Monti C, Zanoni A, Forni C and Manfrini M: Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer. 79:245–254. 1997. View Article : Google Scholar : PubMed/NCBI
10	Navid F, Willert JR, McCarvile MB, Furman W, Watkins A, Roberts W and Daw NC: Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 113:419–425. 2008. View Article : Google Scholar : PubMed/NCBI
11	Berger M, Grignani G, Ferrari S, Biasin E, del Prever Brach A, Aliberti S, Saglio F, Aglietta M and Fagioli F: Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer. 115:2980–2987. 2009. View Article : Google Scholar : PubMed/NCBI
12	Saylors RL III, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R and Vietti TJ; Pediatric Oncology Group, : Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study. J Clin oncol. 19:3463–3469. 2001. View Article : Google Scholar : PubMed/NCBI
13	Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, et al: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcoma: Results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 25:2755–2763. 2007. View Article : Google Scholar : PubMed/NCBI
14	Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, Wesley R and Magrath I: Ifosfomide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 5:1191–1198. 1987. View Article : Google Scholar : PubMed/NCBI
15	Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M and Grier HE: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. J Clin Oncol. 20:426–433. 2002. View Article : Google Scholar : PubMed/NCBI
16	Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G and Cairo MS: Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The children's cancer group (CCG) experience. Pediatr Blood Cancer. 44:338–347. 2005. View Article : Google Scholar : PubMed/NCBI
17	Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, et al: SFOP OS94: A randomized trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 43:752–761. 2007. View Article : Google Scholar : PubMed/NCBI
18	Anderson PM, Subbiah V and Rohren E: Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: Samarium-153-EDTMP and radium-223. Adv Exp Med Boil. 804:291–304. 2014. View Article : Google Scholar
19	Subbiah V, Rohren E, Huh WW, Kappadath CS and Aderson PM: Phase 1 dose escalation trial of intravenous radium 223 dichloride alpha-particle therapy in osteosarcoma. J Clin Oncol. 32 15-Suppl:Abstract TPS 10600. 2014.
20	Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, et al: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progression after standard treatment: A non-radomised phase 2 clinical trial. Lancet Oncol. 16:90–107. 2015. View Article : Google Scholar
21	Sun L, Li Y, Li H, Zhang J, Li B and Ye Z: Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years. Clin Ther. 36:567–578. 2014. View Article : Google Scholar : PubMed/NCBI
22	Jaffe N: Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer. 30:1627–1631. 1972. View Article : Google Scholar : PubMed/NCBI
23	Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C and Huvos AG: Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer. 43:2163–2177. 1979. View Article : Google Scholar : PubMed/NCBI
24	Rosen G and Nirenberg A: Neoadjuvant chemotherapy for osteogenic sarcoma: A five year follow-up (T-10) and preliminary report of new studies (T-12). Prog Clin Biol Res. 201:39–51. 1985.PubMed/NCBI
25	Rosen G: Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: A ten year experience. Orthopedics. 8:659–664. 1985.PubMed/NCBI
26	Thiele OC, Freier K, Bacon C, Egerer G and Hofele CM: Interdisciplinary combined treatment of craniofacial osteosarcoma with neoadjuvant and adjuvant chemotherapy and excision of the tumour: A retrospective study. Br J Oral Maxillofac Surg. 46:533–536. 2008. View Article : Google Scholar : PubMed/NCBI
27	Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V and Rosen G: Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol. 10:5–15. 1992. View Article : Google Scholar : PubMed/NCBI
28	Eilber FR and Rosen G: Adjuvant chemotherapy for osteosarcoma. Semin Oncol. 16:312–322. 1989.PubMed/NCBI
29	Rosen G: Neoadjuvant chemotherapy for osteogenic sarcoma: A model for the treatment of other highly malignant neoplasms. Recent Results Cancer Res. 103:148–157. 1986. View Article : Google Scholar : PubMed/NCBI
30	Su W, Lai Z, Wu F, Lin Y, Mo Y, Yang Z and Wu J: Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: Meta-analysis of randomized controlled trials. Med Oncol. 32:4812015. View Article : Google Scholar : PubMed/NCBI
31	Li S, Sun W, Wang H, Zuo D, Hua Y and Cai Z: Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal. Tumor Biol. 36:1329–1338. 2015. View Article : Google Scholar
32	van Dalen EC, van der Pal HJ, Caron HN and Kremer LC: Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev: CD005008. 2006. View Article : Google Scholar
33	Liu Y, Xu Y, Lin N, Jiang S, Wang Y and Ye Z: High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma. Cell Biochem Biophys. 71:1097–1104. 2015. View Article : Google Scholar : PubMed/NCBI
34	Holmboe L, Andersen AM, Mørkrid L, Slørdal L and Hall KS: High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 73:106–114. 2012. View Article : Google Scholar : PubMed/NCBI
35	Zhang W, Zhang Q, Zheng TT, Zhen JC and Niu XH: Delayed high-dose methotrexate excretion and influencing factors in osteosarcoma patients. Chin Med J (Engl). 129:2530–2534. 2016. View Article : Google Scholar : PubMed/NCBI
36	Kaneko T, Fujioka T, Suzuki Y, Sato Y and Itoh H: Performance characteristics between TDx^®FLx and TBA™-25FR for the therapeutic drug monitoring of methotrexate. J Pharm Health Care Sci. 2:72016. View Article : Google Scholar : PubMed/NCBI
37	Yu W, Tang L, Lin F, Yao Y and Shen Z: Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter? Med Onco. 32:3072015. View Article : Google Scholar
38	Kobys VL, Konovalenko VF, Repinа NV, Golovko TS, Gulak LO, Tarasova TO, Zaharycheva EV and Matyushok OF: Treatment of large osteosarcoma in children: New approach. Exp Oncol. 35:105–108. 2013.PubMed/NCBI
39	He F, Zhang W, Shen Y, Yu P, Bao Q, Wen J, Hu C and Qiu S: Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis. Int J Surg. 36:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
40	Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y and Huang SH: Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett. 4:878–882. 2012. View Article : Google Scholar : PubMed/NCBI
41	Sampson VB, Gorlick R, Kamara D and Kolb Anders E: A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol. 31:1322013.
42	Huang YJ, He AN, Sun YJ, Shen Z, Min DL and Yao Y: Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: A retrospective study. Asian Pac J Cancer Prev. 16:2391–2395. 2015. View Article : Google Scholar : PubMed/NCBI
43	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
44	Hattinger CM, Vella S, Tavanti E, Fanelli M, Picci P and Serra M: Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. Pharmacogenomics. 17:2097–2114. 2016. View Article : Google Scholar : PubMed/NCBI
45	Duffaud F, Egerer G, Ferrari S, Rassam H, Boecker U and Bui-Nguyen B: A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. Eur J Cancer. 48:564–570. 2012. View Article : Google Scholar : PubMed/NCBI
46	Heymann MF, Brown HK and Heymann D: Drugs in early clinical development for the treatment of osteosarcoma. Expert Opin Investig Drugs. 25:1265–1280. 2016. View Article : Google Scholar : PubMed/NCBI
47	Lee JA, Paik EK, Seo J, Kim DH, Lim JS, Yoo JY and Kim MS: Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma. Jpn J Clin Oncol. 46:138–143. 2016.PubMed/NCBI
48	Qi WX, He AN, Tang LN, Shen Z, Lin F and Yao Y: Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: A retrospective study of 18 patients. Jpn J Clin Oncol. 42:427–431. 2012. View Article : Google Scholar : PubMed/NCBI
49	Wang DZ, Gao JF, Jing SF, Wei H, Huang XY and Li CD: Antitumor effect of docetaxel in osteosarcoma by the inhibition of Wnt signal channel. Drug Res (Stuttg). 65:597–601. 2015.PubMed/NCBI
50	Choi J, Ko E, Chung HK, Lee JH, Ju EJ, Lim HK, Park I, Kim KS, Lee JH, Son WC, et al: Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs. Int J Nanomedicine. 10:6121–6132. 2015. View Article : Google Scholar : PubMed/NCBI
51	He A, Qi W, Huang Y, Sun Y, Shen Z, Zhao H, Yang Y and Yao Y: Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: A single institution experience. Int J Clin Oncol. 18:498–505. 2013. View Article : Google Scholar : PubMed/NCBI
52	Xiao X, Wang W, Zhang H, Gao P, Fan B, Huang C, Fu J, Chen G, Shi L, Zhu H, et al: Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma. Tumour Biol. 36:2427–2435. 2015. View Article : Google Scholar : PubMed/NCBI
53	Palmerini E, Jones RL, Marchesi E, Paioli A, Cesari M, Longhi A, Meazza C, Coccoli L, Fagioli F, Asaftei S, et al: Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer. 16:2802016. View Article : Google Scholar : PubMed/NCBI
54	Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, Seibel N, Chen Z, Strain J and Reaman G; Children's Oncology Group, : Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: A report from the Children's Oncology Group. Cancer. 106:1821–1828. 2006. View Article : Google Scholar : PubMed/NCBI
55	Song BS, Seo J, Kim DH, Lim JS, Yoo JY and Lee JA: Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea cancer center hospital experience. Pediatr Blood Cancer. 61:1376–1381. 2014. View Article : Google Scholar : PubMed/NCBI
56	Lee JA, Jeon DG, Cho WH, Song WS, Yoon HS, Park HJ, Park BK, Choi HS, Ahn HS, Lee JW, et al: Higher gemcitabine dose was associated with better outcome of osteosarcoma patients receiving gemcitabine-docetaxel chemotherapy. Pediatr Blood Cancer. 63:1552–1556. 2016. View Article : Google Scholar : PubMed/NCBI
57	Strippoli S, Traversa M, Cramarossa A, Popescu O, Lorusso V and Guida M: Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report. Oncol Lett. 9:2567–2571. 2015. View Article : Google Scholar : PubMed/NCBI
58	Yu WX, Tang LN, Lin F, Yao Y and Shen Z: Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute. Oncol Lett. 8:2243–2248. 2014. View Article : Google Scholar : PubMed/NCBI
59	Mora J, Cruz CO, Parareda A and de Torres C: Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 31:723–729. 2009. View Article : Google Scholar : PubMed/NCBI
60	O'Day K and Gorlick R: Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther. 9:511–523. 2009. View Article : Google Scholar : PubMed/NCBI
61	Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, et al: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study. Ann Oncol. 23:508–516. 2012. View Article : Google Scholar : PubMed/NCBI
62	Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, et al: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial. Lancet Oncol. 16:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
63	Magnan H, Goodbody CM, Riedel E, Pratilas CA, Wexler LH and Chou AJ: Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. Pediatr Blood Cancer. 62:594–597. 2015. View Article : Google Scholar : PubMed/NCBI
64	Liu L and Bhatoolaul N: Endostar as a perioperative regimen with chemotherapy in osteosarcoma: A Review. Biomed Lett. 2:60–65. 2016.
65	Hattinger CM, Tavanti E, Fanelli M, Vella S, Picci P and Serra M: Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. Expert Opin Drug Metab Toxicol. 13:245–257. 2016. View Article : Google Scholar : PubMed/NCBI
66	Zhu X, Du X, Deng X, Yi H, Cui S, Liu W, Shen A and Cui Z: C6 ceramide sensitizes pemetrexed-induced apoptosis and cytotoxicity in osteosarcoma cells. Biochem Biophys Res Commun. 452:72–78. 2014. View Article : Google Scholar : PubMed/NCBI
67	Xu M, Xu CX, Bi WZ, Song ZG, Jia JP, Chai W, Zhang LH and Wang Y: Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone. 57:111–115. 2013. View Article : Google Scholar : PubMed/NCBI
68	Venkatakrishnan K, Kramer WG, Synold TW, Goodman DB, Sides E III and Oliva C: A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers. Eur J Clin Pharmacol. 68:1347–1355. 2012. View Article : Google Scholar : PubMed/NCBI
69	Mori K, Ando K and Heymann D: Liposomal muramyl tripeptide phosphatidyl ethanolamine: A safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther. 8:151–159. 2008. View Article : Google Scholar : PubMed/NCBI
70	Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Mullan BP and Bruland OS: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 20:189–196. 2002. View Article : Google Scholar : PubMed/NCBI
71	Lin F, Zheng SE, Shen Z, Tang LN, Chen P, Sun YJ, Zhao H and Yao Y: Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol. 28:649–653. 2011. View Article : Google Scholar : PubMed/NCBI
72	Qu L and Liu B: Cyclooxygeanse-2 promotes metastasis in osteosarcoma. Cancer Cell Int. 15:692015. View Article : Google Scholar : PubMed/NCBI
73	Kleinerman ES: Current advances in osteosarcoma. Springer International Publishing Switzerland. 35:5942014.
74	Endo-Munoz L, Evdokiou A and Saunders NA: The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim Biophys Acta. 1826:434–442. 2012.PubMed/NCBI
75	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
76	Geller DS and Gorlick R: Osteosarcoma: A review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
77	Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: Where do we go from here? Paediatr Drugs. 10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
78	van Oosterwijk JG, Anninga JK, Gelderblom H, Cleton-Jansen AM and Bovée JV: Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol Oncol Clin North Am. 27:1021–1048. 2013. View Article : Google Scholar : PubMed/NCBI
79	Savage SA and Mirabello L: Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011:5481512011. View Article : Google Scholar : PubMed/NCBI
80	ESMO/European Sarcoma Network Working Group: Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25 Suppl 3:iii113–iii123. View Article : Google Scholar : PubMed/NCBI
81	Wang J and Li G: Mechanisms of methotrexate resistance in osteosarcoma cell lines and strategies for overcoming this resistance. Oncol Lett. 9:940–944. 2015. View Article : Google Scholar : PubMed/NCBI
82	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
83	Miller BJ, Cram P, Lynch CF and Buckwalter JA: Risk factors for metastatic disease at presentation with osteosarcoma: An analysis of the SEER database. J Bone Joint Surg Am. 95:e892013. View Article : Google Scholar : PubMed/NCBI
84	Botter SM, Neri D and Fuchs B: Recent advances in osteosarcoma. Curr Opin Pharmacol. 16:15–23. 2014. View Article : Google Scholar : PubMed/NCBI
85	Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, Olson TA, Wasilewski-Masker K, Alazraki A and Katzenstein HM: Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 59:854–858. 2012. View Article : Google Scholar : PubMed/NCBI
86	Gosiengfiao Y, Reichek J, Woodman J, Ben-Ami T and Walterhouse D: Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: The experience at children's memorial hospital. J Pediatr Hematol Oncol. 34:e63–e65. 2012. View Article : Google Scholar : PubMed/NCBI